Article info
PDFPostScript
Letter
Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathology
- Correspondence to Dr Luke Dixon, Department of Imaging, Imperial College Healthcare NHS Trust, London, London, UK; luke.dixon1{at}nhs.net
Citation
Immunosuppression for intracranial vasculitis associated with SARS-CoV-2: therapeutic implications for COVID-19 cerebrovascular pathology
Publication history
- Received June 17, 2020
- Revised July 21, 2020
- Accepted August 5, 2020
- First published August 27, 2020.
Online issue publication
February 24, 2021
Article Versions
- Previous version (15 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage